Trial Profile
Bictegravir, Emtricitabine and Tenofovir Alafenamide in Transwomen for Optimization of ART: The (mo)BETTA Trial
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir alafenamide
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms (mo)BETTA
- 24 Jan 2022 Status changed from recruiting to discontinued.
- 26 Apr 2021 Planned End Date changed from 1 Apr 2020 to 1 May 2022.
- 26 Apr 2021 Planned primary completion date changed from 1 Apr 2020 to 1 May 2022.